Compare PTRN & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTRN | LGND |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | 2300 | 68 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | N/A | N/A |
| Metric | PTRN | LGND |
|---|---|---|
| Price | $28.02 | $303.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $19.56 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 2.6M | 489.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.89 | $1.25 |
| Revenue Next Year | $22.19 | $19.41 |
| P/E Ratio | ★ N/A | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.19 | $131.67 |
| 52 Week High | $29.80 | $326.63 |
| Indicator | PTRN | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 66.04 | 59.46 |
| Support Level | $10.48 | $180.85 |
| Resistance Level | N/A | $326.63 |
| Average True Range (ATR) | 1.44 | 11.52 |
| MACD | -0.04 | -4.13 |
| Stochastic Oscillator | 74.38 | 37.96 |
Pattern Group Inc is an e-commerce accelerator that uses its technology platform, data science, and a team of experts to drive growth for brands. The Company acquires inventory from brand partners to sell to consumers, enabling full control over content, pricing, logistics, and customer service. Brand partners that contract with the Company operate in various industries, including health and wellness, beauty and personal care, home and lifestyle, pet, sports and outdoors, and consumer electronics. The Company mainly derives its revenue in the United States by selling products to customers via online marketplaces. The company genrates majority of revenue from the US.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.